Breaking away from the money game over license fees
As license fees become more expensive, so do therapeutic drugs, resulting in increased patient burden and higher medical costs.
PtBio's exclusive license for ZF-ND1 avoids expensive license fees. Also, there is no risk of paying license fees to multiple right holders.
Application to gene therapy for intractable diseases
We are currently working with VC Gene Therapy and Hiroshima University to develop a gene therapy for retinitis pigmentosa, for which an effective treatment has not yet been established, for medical application.
PtBio has signed a license agreement for ZF-ND1 with VC Gene Therapy, a company founded by Dr. Masayo Takahashi, a top runner in retinal regenerative medicine.
Advanced genome editing technology is required to master ZF-ND1, but our team has overcome the hurdles to realize its efficacy and safety and is well on its way to commercialization.
